A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-10... von Banerjee, Susana, Eskander, Ramez, Roxburgh, Patricia, O'Malley, David, Oaknin, Ana, Barlin, Joyce, Van Nieuwenhuysen, Els, Anderson, Charles, Baurain, Jean-François, Brubaker, Lindsay, Ang, Joo Ern, Cloven, Noelle, Redondo, Andrés, Monk, Bradley, Ray-Coquard, Isabelle, Moore, Kathleen, Berton, Dominique, Sardone, Megan, Marsolini, Diane, Westin, Shannon

Volltext

Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors von Banerji, Udai, Pacey, Simon, Finkelstein, Karen, Rodney, Simon, DosReis, Ana Filipa Palma, Codaccipisanelli, Giovanni, Sloan, Mark, Raynaud, Florence I, Ruddle, Ruth, Swales, Karen, Tall, Matthew, Shemesh, Shay, Marsolini, Diane, Sardone, Megan, Hay, Justin, Bliss, Robin, Poradosu, Enrique, Workman, Paul

Volltext

A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800101... von Banerjee, Susanaoh, Eskander, Ramez, Roxburgh, Patricia, O'Malley, David, Oaknin, Ana, Barlin, Joyce, Van Nieuwenhuysen, Els, Anderson, Charles, Baurain, Jean-Francois, Brubaker, Lindsay, Ang, Joo Ern, Cloven, Noelle, Redondo, Andres, Monk, Bradley, Ray-Coquard, Isabelle, Moore, Kathleen, Berton, Dominique, Sardone, Megan, Marsolini, Diane, Westin, Shannon

Volltext